This is a multicenter, prospective, observational cohort study enrolling 392 patients with stage I-III radically resectable colon adenocarcinoma carrying at least one oncogenic driver mutation (KRAS, NRAS, BRAF, PIK3CA). Serial plasma ctDNA-MRD testing via a standardized 10-gene NGS panel will be performed at predefined time points during 3-year postoperative follow-up. The primary objective is to evaluate the correlation between postoperative ctDNA-MRD status and recurrence-free survival (RFS). Secondary objectives include overall survival (OS), time advantage of MRD for early recurrence warning ahead of radiology, and correlation between dynamic MRD changes and adjuvant treatment efficacy. Exploratory analysis will compare MRD detection rate and prognostic performance across distinct driver mutation subtypes, aiming to build an integrated risk stratification model combining driver genotype and longitudinal MRD monitoring to guide individualized adjuvant therapy for colon cancer patients.
Longitudinal ctDNA-MRD NGS testing at scheduled postoperative time points
1 clinical trials involving this therapy/drug
This is not medical advice - consult your oncologist
Descriptions are automatically translated with AI assistance. Always verify details in the original on ClinicalTrials.gov and consult your treating physician.
NCT07795528ClinicalTrials.gov ↗
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.